Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ad26.ZEBOV, MVA-BN-Filo vaccine effectiveness study in suspected Ebola cases
PACTR202409720685028Not yet recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Jan 2025
- Modality
- Vaccines & Immunotherapeutics, Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 5
01
Overview
Open-label trial of zabdeno and Mvabea in Ebola virus disease (EVD) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: PCR-confirmed diagnostic of Ebola virus disease in suspected cases received at Ebola treatment unit. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
zabdenoMvabea
03
Conditions
Ebola virus disease (EVD)
Beyond the preview
Go deeper on PACTR202409720685028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202409720685028.